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Abstract 
Aclidinium is a twice-daily long-acting muscarinic receptor antagonist (LAMA) with an 
interesting pharmacological profile. Recent evidence indicates that this LAMA, in addition 
to causing a significant improvement in lung function and other important supportive 
outcomes, such as health related quality of life, dyspnea and nighttime/early morning 
symptoms in patients suffering from COPD, is also able to significantly reduce the rate of 
exacerbations of any severity, is extremely effective in controlling the COPD symptoms, is 
able to reduce lung hyperinflation, and has an excellent cardiovascular safety profile. 
Consequently, aclidinium should be considered a first-line approach at least for the 
symptomatic treatment of COPD although there are still few head-to-head studies 
comparing this LAMA with other bronchodilators. In any case, aclidinium can be taken into 
account in the treatment of different COPD phenotypes (emphysema, chronic bronchitis, 
exacerbators and patients with overlap COPD asthma). 
Key words 
Aclidinium, COPD, phenotypes. 
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Introduction 
Airway tone is mainly controlled by the vagus nerve [1]. Acetylcholine (ACh), the 
neurotransmitter of the parasympathetic nervous system, acts via activation of muscarinic 
receptors [1]. Under “physiological” conditions, the airway smooth muscle contraction 
induced by ACh is mediated primarily via the M3 subtype, whereas the M2 subtype 
couples to adenyl cyclase via Gi in an inhibitory manner [1]. 
There is solid documentation that parasympathetic activity is increased in patients with 
chronic obstructive pulmonary disease (COPD) and appears to be the major reversible 
component of airway obstruction [1]. This primary reversible component is sensitive to 
muscarinic receptor antagonists [2]. Therefore, muscarinic receptor antagonists are central 
to the treatment of COPD [3]. 
There are currently six licensed muscarinic receptor antagonists for use in the treatment of 
COPD, the short-acting muscarinic receptor antagonists (SAMAs), ipratropium bromide 
and oxitropium bromide, and the long-acting muscarinic receptor antagonists (LAMAs), 
aclidinium bromide, tiotropium bromide, umeclidinium bromide, and glycopyrronium 
bromide. 
In this review we will focus on the development of aclidinium and explain its role in the 
long-term, maintenance treatment of bronchospasm associated with chronic obstructive 
pulmonary disease including chronic bronchitis and emphysema. 
Preclinical data 
Pre-clinical development of aclidinium has allowed investigators to collect important 
information that helps explain its positioning in the treatment of COPD. 
In vitro, aclidinium bromide shows kinetic selectivity for human M3 receptors over M2 and 
rapidly associates at recombinant M3 receptors (2.6 times faster than tiotropium) [4]. In 
human bronchial tissue, it has a similar potency at M3 receptors to that of tiotropium and 
ipratropium, although its onset of action is significantly faster than tiotropium and its 
duration of action is significantly longer than ipratropium [5]. Moreover, aclidinium induces 
a potent concentration-dependent relaxation of human precision-cut lung slices 
submaximally pre-contracted with acetylcholine and its potency is not significantly different 
from that of formoterol [6]. 
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In human left atrial tissue, aclidinium has a shorter duration of action at M2 receptors than 
tiotropium, but longer than ipratropium [5]. 
In vitro, aclidinium is rapidly hydrolysed into carboxylic acid and alcohol derivatives in 
KXPDQSODVPD,QFRQWUDVWRIWLRWURSLXPDQGLSUDWURSLXPUHPDLQXQFKDQJHGLQWKH
plasma after 60 min of incubation [7]. The carboxylic acid and alcohol metabolites have no 
significant affinity for any of the muscarinic receptors, and show no relevant 
antibronchoconstrictory activity in vivo. 
Clinical development 
We have already reviewed the clinical development of aclidinium [8]. The critical analysis 
of the data available at the time we wrote the review allowed us to conclude that the twice-
GDLO\SURJUDPHVWDEOLVKHGDFOLGLQLXPȝJWZLFH-daily (BID) as the lowest effective dose 
to achieve clinically meaningful improvements in lung function and other important 
supportive outcomes such as health-related quality of life and dyspnea. We also 
highlighted that maximum bronchodilation is achieved after the first dose and persists over 
the time, the effect is similar to that observed with tiotropium and formoterol and the safety 
database meets regulatory standards and GHPRQVWUDWHVDFOLGLQLXPȝJ WZLFH-daily is 
well-tolerated, safe and effective with a positive benefit/risk profile. 
Later, other information was delivered to the literature that allows us to better clarify the 
role of aclidinium in COPD. Table 1 reports the fundamental trials with aclidinium in COPD. 
Onset of action 
A translational study that has compared, in the same patients and human tissues, the 
onset of action of aclidinium, glycopyrronium and tiotropium has shown that in isolated 
airways, glycopyrronium elicited a dose-dependent onset of action that was faster 
compared to that induced by aclidinium and tiotropium, which halved the contractile tone 
only at the highest concentration [9]. Nine, eight and twelve out of sixteen COPD patients 
did not achieve 15% increase of FEV1 after inhalation of aclidinium 400 µg, 
glycopyrronium 50 ȝg and tiotropium 18 µg, respectively. In responders, aclidinium 
(15.6±7.5 min) and glycopyrronium (17.9±10.4 min) enhanced 15% FEV1 more rapidly 
than tiotropium (42.5±19.4 min). These data suggest the importance of the association 
rate with M3 receptor in influencing onset of bronchodilation of LAMAs, but due to small 
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sample sizes of responders in our trial, the true difference in onset of action between 
aclidinium, glycopyrronium and tiotropium remains unclear. 
Recently, Santus et al. [10] demonstrated that both aclidinium and glycopyrronium 
significantly reduce hyperinflation and dyspnoea in severe and very severe COPD 
patients. Aclidinium however promoted a faster reduction in residual volume (5 min vs. 60 
min) and was the only able to reduce lung ventilation inhomogeneity. 
Impact on lung function over time 
A 52-week, double-blind, extension study, in which COPD patients previously treated with 
DFOLGLQLXP  ȝJ RU  ȝJ %,' GXULQJ D -week lead-in study (ACCORD COPD I) 
continued the same treatment, while patients previously receiving placebo were re-
UDQGRPL]HGWRDFOLGLQLXPȝJRUȝJ%,'DVVHVVHGWKHORQJ-term efficacy of 
aclidinium in pulmonary function [11@3DWLHQWVZKRUHFHLYHGFRQWLQXRXVDFOLGLQLXPȝJ
RUȝJGHPRQVWUDWHG LPSURYHPHQWV IURPEDVHOLQH LQPRUQLQJSUHGRVH WURXJK)(91 
throughout the extension studies. Patients who were re-UDQGRPL]HGWRDFOLGLQLXPȝg 
RUȝJIURPSODFHER at the end of the 12-week ACCORD COPD I study demonstrated 
improvements from baseline in trough FEV1 12 weeks after initiation of treatment with 
DFOLGLQLXPȝJRUȝJ that were similar to those recorded at the end of 12 weeks of 
the ACCORD COPD I study LQ SDWLHQWV WUHDWHG ZLWK DFOLGLQLXP  ȝJ RU  ȝJ
respectively. However, patients re-randomized from placebo to DFOLGLQLXPȝJshowed 
a fall in trough FEV1 at the end of 52-week extension, contrary to that observed in other 
treatment arms and, in particular in those that, already treated with aclidinium 200 ȝJ, 
continued the same treatment, in which the improvement in trough FEV1 was maintained. 
In another 52-week trial conducted in the U.S. and Canada, which enrolled 605 patients 
with moderate-to-VHYHUH&23'ZKRZHUHUDQGRPL]HGWRDFOLGLQLXPȝJRUȝJ%,', 
the improvement in trough FEV1 observed at the beginning of the study was generally 
maintained until study enG ZLWK WKH DFOLGLQLXP  ȝJ GRVH ZLWK PHDQ FKDQJHV IURP
baseline in trough FEV1 of 72 mL at the end of the study [12]. Numerically greater 
LQFUHDVHVZHUHGHWHFWHGZLWKWKHȝJGRVHFRPSDUHGZLWKWKHȝJGRVHIRUDOOOXQJ
function parameters throughout the study, indicating a dose-dependent effect on 
bronchodilation throughout 1 year of treatment. 
Impact on breathlessness, health status, and COPD symptoms  
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Significant improvements were seen in breathlessness, health status, and COPD 
symptoms in the pivotal trials, but there has been a paucity of comparisons of aclidinium 
vs. other bronchodilators.  
Data of 1787 patients with moderate-to-severe COPD from three 6-month, placebo-
controlled Phase III trials evaluating aclidinium mono- or combination-therapy showed that 
aclidinium significantly improved breathlessness assessed using the Transitional 
Dyspnoea Index (TDI) and the health status assessed using the St George's Respiratory 
Questionnaire (SGRQ) vs. placebo after a 6-month treatment regardless of GOLD 2013 
classification Group [13]. 
In a pre-specified analysis of pooled data from two 24-week, double-blind, parallel-group, 
active- and placebo-controlled, multicentre, randomised Phase III studies (ACLIFORM and 
AUGMENT), overall, 55.7% of patients achieved the minimum clinically important 
difference in TDI focal score with aclidinium, compared with 57.0% with formoterol and 
40.3% with placebo [14]. 
In the 12-month extension study in the ACCORD COPD I cohort, patients who received 
FRQWLQXRXV WUHDWPHQW ZLWK DFOLGLQLXP  ȝJ VKRZHG FOLQLFDOO\ VLJQLILFDQW LPSURYHPHQWV
from baseline in total SGRQ scores, with an improvement of 7.9 units observed by the end 
of the study [11]. Also in the U.S. and Canada 52-week trial, aclidinium 400 ȝJ induced 
clinically meaningful LPSURYHPHQWV LQ 6*54 WRWDO VFRUHV -point reduction from 
baseline) at all study visits during the entire treatment period [12]. A numerically higher 
proportion of patients LQWKHDFOLGLQLXPȝJJURXSachieved the difference of at least 4 
units (the threshold of clinical significance) in SGRQ total score versus the ȝJJURXS
throughout the study. 
Ni et al. [15] performed a Cochrane review from twelve aclidinium clinical studies, the 
duration of which ranged from four weeks to 52 weeks, in 9,547 COPD patients. Data from 
7 trials with 4442 participants documented that aclidinium had been able to improve quality 
of life by lowering the SGRQ total score with a mean difference of -2.34 when compared to 
placebo. More patients on aclidinium achieved a clinically meaningful improvement of at 
least four units decrease in SGRQ total score (OR 1.49; number needed to treat (NNT) = 
10) over 12 to 52 weeks than on placebo. 
The pooled analysis of two Phase III studies (ATTAIN and AUGMENT) documented that in 
patients with moderate to severe airflow obstruction, aclidinium 400 µg BID significantly 
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improved daily respiratory symptoms assessed using the EXAcerbations of Chronic 
pulmonary disease Tool-Respiratory Symptoms (E-RS) diary, and increased the net 
response rate compared to placebo, but improvements in E-56WRWDOVFRUHunits were 
seen with aclidinium in patients in GOLD groups B + D (i.e., those with more symptoms) 
[16]. 
In a 6-week study of Beier et al. [17] comparing aclidinium 400 µg BID with placebo and 
tiotropium 18 µg QD in patients with stable, moderate to severe COPD, significant 
improvements in the E-RS total scores over 6 weeks were numerically greater with 
aclidinium than tiotropium versus placebo. Both aclidinium and tiotropium significantly 
improved morning trough FEV1 and FVC compared with placebo on day 1 and at week 6. 
Improvements in FEV1 area under the curve from 0 to 12 h (AUC0–24) and FEV1 area 
under the curve from 12 to 24 h (AUC12–24 were significantly greater with aclidinium versus 
tiotropium on day 1. Over 6 weeks, FEV1 AUC0–12 and FEV1 AUC12–24 with aclidinium 
were, respectively, numerically smaller and greater than tiotropium, but differences 
between the two treatments were not statistically significant. Nevertheless, aclidinium, but 
not tiotropium, produced significant improvements in individual early morning phlegm, 
shortness of breath, wheeze, cough and nighttime symptoms compared with placebo at 
week 6. It is possible to assume that the greater nighttime numerical improvement in lung 
function induced by aclidinium in the second 12 hours translated into significant changes 
in patient-reported outcomes. In any case, the limitation of activity caused by COPD 
symptoms was significantly lower only in patients receiving aclidinium versus those 
receiving placebo. 
The pooled analysis of the ATTAIN and AUGMENT studies showed that the percentage of 
patients achieving a reduction in E-56WRWDOVFRUHRIXQLWVZDV41.3% with aclidinium, 
compared with 42.3% with formoterol and 34.4% with placebo [14]. The same pooled 
analysis documented that improvements in overall night-time symptom severity 
(aclidinium: – XQLWV IRUPRWHURO í XQLWV DQG HDUO\-morning symptom severity 
DFOLGLQLXPíXQLWVIRUPRWHUROíXQLWVZHUHDOPRVWLGHQWLFDO>@ 
A recent real-life experience with aclidinium showed that after approximately 3 months of 
treatment, the severity of COPD-related nighttime and early-morning symptoms and the 
limitation of morning activities were significantly reduced and the health-related quality of 
life relevantly improved under the conditions of daily clinical practice [18]. Interestingly, 
beneficial treatment effects were seen in patients with newly diagnosed COPD as well as 
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in patients with a history of COPD or previously treated with another LAMA, although 
improvements in the patient-reported outcomes were greater in newly diagnosed patients 
than in patients with previously known COPD. 
Three Phase III studies (ACCORD COPD I [12 weeks], ATTAIN [24 weeks]) and LAS39 [6 
weeks]) assessed the effect of aclidinium 400 µg BID on cough and sputum severity in 
patients with moderate-to-severe COPD (not selected for these symptoms). The 
retrospective analysis of these trials has documented that E-RS cough/sputum domain 
scores were lower with aclidinium than placebo [19]. Morning and nighttime cough 
severity, morning difficulty bringing up phlegm and nighttime sputum production were also 
reduced with aclidinium.  
Rescue medication use 
In the 6-week study of Beier et al. [17], the impact of aclidinium and tiotropium has been 
evaluated also on relief medication use and a significant increase in relief medication-free 
days with aclidinium and tiotropium versus placebo has been observed. Also in the 12-
month extension study in the ACCORD COPD I cohort [11] and in the other 12-month trial 
[12], a decrease in medication use was recorded. In particular, in the Gelb’s trial [12], 
rescue medication use during the overall treatment period was approximately one-half of 
the baseline value.  
Impact on COPD exacerbations 
In a pooled analysis of Phase III trials that included 2521 patients, aclidinium significantly 
reduced the rate of exacerbations of any severity vs. placebo for all patients [20]. The rate 
reduction was mainly in symptomatic patients (GOLD groups B + D). Time to first 
exacerbation (any) was delayed with aclidinium 400 µg vs. placebo in GOLD groups B+D 
but not GOLD groups A + C.  
In their Cochrane review, Ni et al. [15], using data from ten aclidinium clinical studies in 
5,624 COPD patients, found that the reduction in moderate exacerbations requiring 
treatment with systemic steroids and/or antibiotics did not reach significance for aclidinium 
versus placebo, but aclidinium significantly reduced the frequency of exacerbations 
requiring hospitalization. 
A network meta-analysis of 27 randomized, controlled trials of at least 12 weeks duration, 
comparing a LAMA with placebo or another LAMA, documented that all LAMAs were able 
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to reduce the rate of moderate-to-severe exacerbations AECOPD when compared to 
placebo, but that there were not substantially differences between them [21]. When the 
analysis was restricted to studies in which the treatment lasted for at least 6 months, 
aclidinium was associated with the lowest risk for severe exacerbations. 
Impact on exercise endurance and lung hyperinflation 
A randomized, double-blind Phase IIIb crossover study evaluated the effect of aclidinium 
ȝJ%,'RQcycling exercise endurance, exertional dyspnea, and lung hyperinflation in 
112 patients with COPD [22]. After 3 weeks, aclidinium significantly increased endurance 
time, reduced dyspnea intensity at isotime during exercise and improved trough inspiratory 
capacity vs. placebo. Significant improvements in spirometric, plethysmographic, and 
some physical activity parameters were also observed with aclidinium versus placebo. 
Safety 
In the 12-month extension of the ACCORD COPD I study, treatment-emergent adverse 
events (TEAEs) were mostly mild to moderate in severity and reported by similar 
percentages of patients across all treatment sequences ȝJȝJ
during extension phase [11]. The manifestation of the classic adverse effects caused by 
antimuscarinic drugs was very low with both doses, so much that the most classic adverse 
effect, dry mouth, appeared in only 1 SDWLHQW ZLWK WKH KLJKHVW GRHV  ȝJ Also as 
regards the heart, both doses were safe causing TEAEs in <5% of treated patients with no 
evidence of a dose-dependent impact 
Also in the second 12-month trial [12], which like the other trials of aclidinium excluded 
patients with a history of clinically significant cardiovascular (CV) disorders, there was no 
difference in the percentage of TEAEs, which in general were mild or moderate, between 
the two doses of aclidinium. The percentages of patients with dry mouth (ȝJ
 ȝJ ) and FRQVWLSDWLRQ  ȝJ   ȝJ  ZKLFK DUH WKH FODVVLF
TEAEs caused by anticholinergic agents, was low across treatment groups. Only few 
patients (always <2% for any event in any group) reported CV TEAEs including coronary 
artery disease (the most frequent cardiac event), which occurred in 1.6% of patients 
receiving 200 ȝJ aclidinium and none receiving the 400 ȝJ dose and atrial fibrillation that 
was similarly uncommon in the two treatment groups (0.6 – 0.7%) Apparently, these 
TEAEs were not dose dependent. 
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A pooled analysis of six Phase III, placebo-controlled, parallel-JURXSVWXGLHVPRQWKWR
1 year duration) that included 2781 patients with moderate-to-severe COPD documented 
the optimum safety of aclidinium 400 µg BID that overall did not differ from that of placebo  
[23]. In particular, it was possible to document the absolute CV and cerebrovascular safety 
of aclidinium even in patients with CV risk factors. 
Conclusion 
Further research on aclidinium ȝJWZLFH-daily that followed the pivotal clinical trials not 
only confirmed that this LAMA induces clinically meaningful effects in lung function and 
other important supportive outcomes, such as health related quality of life, dyspnea and 
nighttime/early morning symptoms, and is safe, but also showed that aclidinium 
significantly reduces the rate of exacerbations of any severity, is extremely effective in 
controlling the COPD symptoms, is able to reduce lung hyperinflation, and has an 
excellent cardiovascular safety profile. 
Expert commentary & five-year view 
It is now widely ascertained the choice of a bronchodilator to treat the diagnosed COPD 
condition depends mainly on individual response, cost, side effects, and availability, and 
therapy often starts with an empiric choice and recording of clinical response to treatment 
[24, 25]. This empiric choice is mainly caused by the fact that there are still some crucial 
questions regarding the use of bronchodilators that require clarification. In particular, we 
still do not know whether LW LVEHWWHU WRVWDUWZLWKDȕ2-agonist or with an anti-muscarinic 
agent, it is useful to use a bronchodilator with rapid onset of action, and it is preferable to 
administer a bronchodilator on a once- or twice-daily basis [26].  
We believe that the choice of bronchodilator to start treatment with in a patient with COPD 
mainly depends on the outcome of interest [25, 26]. LAMAs are probably preferable 
because in the symptomatic patient there is no substantial difference between them and 
LABAs [27], whereas in frequent exacerbators, they are more effective [28]. Although it is 
not yet clear if the differences in bronchodilator onset of action (fast-onset action versus 
slow-onset action) have any clinical role in COPD [26], we fully share the view that a 
bronchodilator with a rapid onset of action could be more effective on morning symptoms 
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than those with a relatively slow onset of action by providing a rapid relief of symptoms 
after morning dosing [29].  
With regard to the question whether it is preferable to choose once- or twice-daily dosing, 
a population pharmacodynamic model of the longitudinal FEV1 response to an inhaled 
LAMA in COPD patients has suggested that with the same total daily dose of a LAMA, a 
twice-daily regimen provides higher bronchodilation at trough than a once-daily regimen, 
the maximum FEV1 response to once-daily regimen is higher, while the predicted average 
FEV1 response is about the same [30]. Consequently, if there is the need for controlling 
both the nocturnal symptoms and those present on awakening, which epidemiological 
studies indicate to be the most troublesome for COPD patients [31], the twice-daily dosing 
of bronchodilators should be considered the most useful approach. 
The results of the various studies conducted in recent years already described show that 
aclidinium is not only a LAMA with an excellent pharmacological profile, but also that it 
induces a rapid onset of action and is extremely effective in controlling nighttime and early-
morning symptoms. This means that aclidinium should be considered a first-line approach, 
at least for the symptomatic treatment of COPD, although we must admit that there are still 
few head-to-head studies comparing aclidinium with other bronchodilators. Nonetheless, 
our opinion is reinforced by the documentation of the absolute cardiovascular safety, 
something that is very important in view of the frequent occurrence of cardiovascular 
diseases in patients with COPD [32]. 
Recognition of the heterogeneity of COPD together with the definition of clinical 
phenotypes suggests that we might take on a more personalized treatment not only 
according to the severity of the airflow obstruction, but also conditioned by the clinical 
phenotype [33]. Different phenotypes characterised by the combination of the classical 
types of emphysema, chronic bronchitis, exacerbators and patients with overlap COPD 
asthma have been identified [34]. Chronic bronchitis in patients with COPD is associated 
with worse respiratory symptoms and a higher risk of exacerbations of COPD [35]. 
Aclidinium can be considered in the treatment of all these phenotypes. In fact, we have 
already described the evidence showing that this LAMA lowers the rate of exacerbations 
of any severity and is able to reduce lung hyperinflation. Aclidinium has not been tested in 
asthmatic patients, but it is in the same class as tiotropium, which is an effective therapy in 
asthma [36]. Furthermore, it was found to reduce allergen-induced hyperresponsiveness 
and eosinophilic airway inflammation in an acute model of asthma [37]. 
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Nevertheless, there is currently a trend to co-administer a LAMA and a LABA in order to 
optimize bronchodilation [38]. Actually, the combination of aclidinium and formoterol 
induces moderate to strong synergistic interaction in relaxing human isolated bronchi [6] 
that has a role also in the clinic setting [39]. However, there is evidence that the regular 
addition of formoterol to aclidinium improved the SGRQ total score more than formoterol (-
6.57 units, and -4.70 units mean changes from baseline at week 24, respectively), but not 
more than aclidinium (-6.44 units) [40]. This finding makes it possible to question whether 
we should always use the dual bronchodilation instead of aclidinium monotherapy. Only a 
large, prospective real life study, in which patients under regular treatment with aclidinium 
will be enrolled and in one of the two arms formoterol will be added to aclidinium while in 
the other arm patients continue to take aclidinium alone, will tell us which patients can take 
a real advantage of the addition of formoterol to aclidinium. 
Key issues 
x Parasympathetic activity is increased in patients with COPD and appears to be the 
major reversible component of airway obstruction. This primary reversible component 
is sensitive to muscarinic receptor antagonists. Therefore, muscarinic receptor 
antagonists are central to the treatment of COPD. 
x Aclidinium is a twice-daily LAMA with an interesting pharmacological profile. 
x Pivotal trials have shown that aclidinium induces clinically meaningful effects in lung 
function and other important supportive outcomes (health related quality of life, 
dyspnea and nighttime/early morning symptoms) and is a safe bronchodilator. 
x Recent evidence indicates aclidinium significantly reduces the rate of exacerbations of 
any severity, is extremely effective in controlling the COPD symptoms, is able to 
reduce lung hyperinflation, and has an excellent cardiovascular safety profile. 
x Aclidinium should be considered a first-line approach at least for the symptomatic 
treatment of COPD, but there are still few head-to-head studies comparing this LAMA 
with other bronchodilators. 
x It can be considered in the treatment of different COPD phenotypes (emphysema, 
chronic bronchitis, exacerbators and patients with overlap COPD asthma). 
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x Although the addition of formoterol to aclidinium induces a larger bronchodilation than 
that obtained with aclidinium alone, we still do not know whether we should always use 
the dual bronchodilation instead of aclidinium monotherapy. 
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Table 1 – Fundamental trials with aclidinium in COPD 
Trial Patients 
(n.) 
Treatments Duration Main endpoints 
ATTAIN 818 ACLI ȝJȝJ%,'YV
placebo 
24 weeks Primary endpoint: change from baseline in 
trough FEV1 at week 24.  
Secondary endpoints: change from baseline 
in peak FEV1, number of patients achieving 
DQLPSURYHPHQW-unit in TDI focal score, 
number of patients achieving an improvement 
-units in SGRQ total score at week 24.  
ACCORD I 561 ACLI ȝJȝJ%,'YV
placebo 
12 weeks Primary endpoint: change from baseline in 
trough FEV1 at week 12. 
Secondary endpoints: change from baseline 
in peak FEV1 at week 12. 
ACCORD II 542 ACLI ȝJȝJ%,'YV
placebo 
12 week followed 
by a 40-week 
evaluation of the 
higher dose 
Primary endpoints: trough FEV1 and long-
term safety and tolerability of aclidinium 
treatment.  
 
LAS-MD-35 605 ACLI ȝJȝJ%,' 52 weeks Primary endpoint: change from baseline in 
morning in trough FEV1 at Week 52 and long-
term safety and tolerability of aclidinium 
treatment.  
Secondary endpoints: health status, and 
rescue medication use. 
LAS-MD-36 
(extension 
ACCORD I) 
291 ACLI ȝJȝJ%,' 
(patients previously receiving 
placebo re-randomized to one 
of the two aclidinium doses) 
52 weeks Primary endpoint: long-term safety 
LAS39 414 ACLI ȝJȝJ%,'YV
7,2ȝJ2'RUSODFHER 
6 weeks Primary endpoint: change from baseline in 
normalized FEV1 AUC0–24 at week 6. 
Secondary endpoints: change from baseline 
in normalized FEV1 AUC12–24 and FEV1 
AUC0–12 at week 6 and peak FEV1 and FVC  
ACLIFORM-
COPD 
1,729 $&/,)250)'&ȝJRU
ȝJ$&/,ȝJ)250
ȝJRUSODFHER 
24 weeks Coprimary endpoints: change from baseline to 
week 24 in 1-hour morning postdose FEV1 
and in trough FEV1. 
Secondary endpoints: change from baseline 
in SGRQ total score and improvement in TDI 
focal score at week 24. 
AUGMENT 1,692 $&/,)250)'&ȝJRU
ȝJ$&/,ȝJ)250
ȝJRUSODFHER 
24 weeks Coprimary endpoints: change from baseline to 
week 24 in 1-hour morning postdose FEV1 
and in trough FEV1. 
Secondary endpoints: change from baseline 
in SGRQ total score and improvement in TDI 
focal score at week 24. 
ACLI, aclidinium, FORM, formoterol; TIO, tiotropium; BID, twice-daily; OD, once-daily. 
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